Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Neoplasms 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Multiple Myeloma 1Melanoma 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hemangiosarcoma 1Esophagogastric Cancer 1Esophageal Neoplasms 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Doxorubicin 2selinexor 1ribociclib 1pazopanib 1STA 9090 1Proton Therapy 1Paclitaxel 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disorders of Sex Development × STA 9090 × Clear all
NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡